Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

and we are excited to be moving our clinical program forward. We are very pleased that the MMRC sponsorship has made the rapid initiation of our Phase 2 trials possible and has enabled us to reach out to a larger group of myeloma patients. The thoughtful scientific expertise and collaborative effort of this group have helped speed development of new agents in the field of multiple myeloma," said Lori A. Kunkel, M.D., Chief Medical Officer of Proteolix, Inc.

About the Multiple Myeloma Research Consortium (MMRC)

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 13 Member Institutions: City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, Roswell Park Cancer Institute, Saint Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York, University Health Network (Princess Margaret Hospital), University of Chicago, University of Michigan, and Washington University. In addition to these trials with Proteolix, the MMRC is supporting six other clinical trials exploring several investigative agents.

The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in the today's most promising research areas- genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- According to a new market research ... Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, ... - Global Forecasts to 2019 ", published by MarketsandMarkets, the ... Billion by 2019 with a CAGR of around 10.3% ... Browse   90   ma rket data ...
(Date:3/27/2015)... 27, 2015   Hospira, Inc. (NYSE: ... and the world,s leading provider of injectable drugs ... an evaluation of biosimilarity of its proposed biosimilar, ... Administration (FDA) conditionally approved name of RETACRIT™, compared ... These study data were presented at the National ...
(Date:3/27/2015)... March 27, 2015 RnRMarketResearch.com ... therapeutic market research report of 52 pages with ... business intelligence library. The report "Visceral ... the therapeutic development for Visceral Pain, complete with ... drug target, mechanism of action (MoA), route of ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... May 7, 2012 A new analysis concludes that rituximab, ... treatment responses lasting at least five years in approximately one ... of bleeding due to chronic immune thrombocytopenic purpura (ITP). In ... Blood , the Journal of the American Society ...
... Mass., May 7, 2012  CardioFocus, Inc., developer of ... treatment of atrial fibrillation (AF), announces that its ... the scientific sessions and during a private academic ... Society,s 33rd Annual Scientific Sessions, May 9-12 in ...
Cached Medicine Technology:Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 2Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 3Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012 2Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012 3
(Date:3/28/2015)... 2015 Rocket Pure , a manufacturer ... release of their new natural sunscreen. They are offering ... Both options come with a bonus lip balm sunscreen. ... on Amazon. Click to see the natural sunscreen ... natural sunscreen is made with non-nano zinc oxide and provides ...
(Date:3/28/2015)... Tucson, AZ. (PRWEB) March 28, 2015 ... according to a new study by researchers ... (HSPH). , Produced with the support of the Coffee ... the journal Molecular Psychiatry this past fall, the study—one ... a meta-analysis of genomic data from more than 120,000 ...
(Date:3/28/2015)... Take a bite of warm, gooey pepperoni pizza, ... into the stomach, ready to break down your meal. ... acids run amok, triggering a burning sensation in the ... 60 million Americans have heartburn at least once a ... how it can be stopped. , Heartburn or acid ...
(Date:3/28/2015)... 28, 2015 Thousands of transvaginal ... by C.R. Bard, Inc. continue to move forward ... Court, Southern District of West Virginia, where Bernstein ... the Plaintiffs’ Steering Committee. According to an ... certain defendants named in those lawsuits leave to ...
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... that offers urgent care in Manhattan, recently commemorated its ... care facility in Manhattan. In addition to 24-hour urgent ... ER facilities. , At this time, Emergency Medical ... for abdominal pain, asthma, chest pain, eye injuries, ear ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
... Once-daily Keppra XR(TM) (levetiracetam) extended-release tablets are ... doctors to simplify patients, treatment plans by decreasing ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090410/NY97244 )According to studies ... Neurology , patients are more likely to ...
... Elective Termination of Pregnancy" ( published by AuthorHouse ... exploring the difficulties that some women and their families ... Memorial Hospital, a massive inner-city medical complex, doctors work ... Dr. David Dinsmore, a confident, likable and incredibly good-looking ...
... April 10 Rheumatoid arthritis (RA) is a systemic ... defense system attacks the joints through the thin layer ... the joints. The most visible symptoms of RA are ... and feet. It can cause fatigue, fever, loss of ...
... Dr. Ashish K. Jha of the Harvard School of Public Health ... ... Washington, DC (PRWEB) April 10, 2009 -- Leroy Jones, ... Washington, D.C., has recorded another episode of his podcast series, "Talking ...
... at Washington University School of Medicine in St. Louis ... drugs to affect one of the possible underlying causes ... new treatments. , Scientists used the test to show ... production of a substance known as amyloid beta (A-beta), ...
... Health network of doctors, hospitals and other health care ... Health,s combined 2008 systemwide income from the day-to-day operations ... $463 million, compared to $471 million in 2007. Sutter ... investment income and changes in net unrealized gains and ...
Cached Medicine News:Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 2Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 3Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 4Health News:A Decision Beyond Life and Death: Novel Examines Effects of Controversial Procedure on Patients, Their Families and Doctors 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 3Health News:New Interview on E-Health Records with Dr. Ashish K. Jha of the Harvard School of Public Health on Talking Technology 2Health News:Test quickly assesses whether Alzheimer's drugs are hitting their target 2Health News:Sutter Health Announces 2008 Financial Performance 2Health News:Sutter Health Announces 2008 Financial Performance 3
The Duracon system provides superb articular conformity throughout the range of motion, reducing contact stresses generally associated with wear....
Cruciate retaining, posterior stabilized and constrained components....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
... The TC-PLUS Solution tricompartmental total knee ... with knee arthroplasty. State-of-the-art design and manufacturing ... achieve optimum biomechanical function as well as ... polyethylene tibial insert to keep wear to ...
Medicine Products: